CRISPR Nobelists surrender their own European patents

Charlotte Harrison
DOI: https://doi.org/10.1038/s41587-024-02472-0
IF: 46.9
2024-11-05
Nature Biotechnology
Abstract:A strategic move by lawyers acting for Doudna and Charpentier is the latest twist in the battleground for CRISPR–Cas9 technology.
biotechnology & applied microbiology
What problem does this paper attempt to address?